Randomized clinical trials towards a single‐visit cure for chronic hepatitis C: Oral GSK2878175 and injectable RG‐101 in chronic hepatitis C patients and long‐acting injectable GSK2878175 in healthy participants

Yanli Deng(GlaxoSmithKline (United States)), Martin Leivers(Research Triangle Park Foundation), Ioannis Goulis, Spilios Manolakopoulos(National and Kapodistrian University of Athens), George Papatheodoridis(National and Kapodistrian University of Athens), Tivadar Bányai(Békés Megyei Központi Kórház), Robert Hamatake(Research Triangle Park Foundation), Kelong Han(University of Pittsburgh), Mark A. Deeg(Regulus Therapeutics (United States)), Soumi Lahiri(GlaxoSmithKline (United States)), Gábor Horváth(Buda Health Center), Dickens Theodore, Bernd Jilma(Medical University of Vienna), Shuguang Chen(GlaxoSmithKline (United States)), George Ν. Dalekos(University Hospital of Larissa), Fiona Campbell(University of Birmingham), Michael Huang(Regulus Therapeutics (United States))
Journal of Viral Hepatitis
February 25, 2020
Cited by 32


Related Papers